Investing

Regeneron beats quarterly profit estimates

Published

on

© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo

(Reuters) – Regeneron Pharmaceuticals Inc (NASDAQ:) beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.

Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts’ estimates of $9.56, according to Refinitiv data.

(This story has been corrected to remove reference to Eylea in the headline and paragraph 1)

Read the full article here

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version